Skip to nav Skip to content


July 10, 2019


FDA Issues Biktarvy Label Changes

The U.S. Food & Drug Administration has approved changes to the label for the HIV medication Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) that include:

  • Expanding the patient population to include pediatric patients with HIV weighing at least 25 kg;
  • An update to the Warnings and Precautions Immune Reconstitution Syndrome subsection with autoimmune hepatitis information;
  • An update the Drug Interactions Table 3, information pertaining to the coadministration of Biktarvy with polyvalent cation (PVC) containing-antacids and supplements;
  • An update to the Nonclinical Toxicology Carcinogenesis, Mutagenesis, Impairment of Fertility subsection, with the carcinogenicity data from a 2-year rate study.

The updated label is here.

This website uses cookies

We use cookies to ensure that we give you the best experience on our website. Cookies facilitate the functioning of this site including a member login and personalized experience. Cookies are also used to generate analytics to improve this site as well as enable social media functionality.